VHL Antikörper (Internal Region)

Produktnummer ABIN374715

Produktdetails anti-VHL Antikörper

Target: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Bindungsspezifität: Internal Region

Reaktivität: Human, Maus, Ratte, Hund

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser VHL Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: This antibody is expected to recognize both reported isoforms of VHL (NP_000542.1 and NP_937799.1).

Kreuzreaktivität (Details): Species reactivity (expected):Canine.
Species reactivity (tested):Human, Mouse, Rat,

Aufreinigung: Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide

Immunogen: Peptide with sequence C-RSLVKPENYRRLD, from the internal region of the protein sequence

Anwendungsinformationen

Applikationshinweise: ELISA: 1/128000. Western Blot: 0.01 - 0.03 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Tris saline, pH ~7.3, 0.02 % Sodium Azide, 0.5 % BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu VHL

Target: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Andere Bezeichnung: VHL (VHL Produkte)

Synonyme: HRCA1 antikoerper, RCA1 antikoerper, VHL1 antikoerper, pVHL antikoerper, BcDNA:RH61560 antikoerper, CG13221 antikoerper, DVhl antikoerper, Dmel\\CG13221 antikoerper, Dvhl antikoerper, VHL antikoerper, d-VHL antikoerper, d-vhl antikoerper, dVHL antikoerper, dmVHL antikoerper, vhl antikoerper, rca1 antikoerper, vhl1 antikoerper, hrca1 antikoerper, zgc:158722 antikoerper, Vhlh antikoerper, von Hippel-Lindau tumor suppressor antikoerper, von Hippel-Lindau antikoerper, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antikoerper, von Hippel-Lindau disease tumor suppressor antikoerper, VHL antikoerper, Vhl antikoerper, vhl antikoerper, CpipJ_CPIJ009992 antikoerper

Hintergrund: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.Synonyms: Protein G7, Von Hippel-Lindau disease tumor suppressor

Molekulargewicht: 19.7 kDa (NP_937799.1)

Gen-ID: 7428, 9606

UniProt: P40337

Pathways: Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway